List of Figures
Figure 1: Orphan and Rare Dermatology Drugs Market, 7MM, Epidemiology Patterns for Systemic Sclerosis (Scleroderma), 2017–2024 26
Figure 2: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Humira ($bn), 2006–2024 39
Figure 3: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Ilaris ($bn), 2009–2024 41
Figure 4: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Afinitor ($bn), 2008–2024 43
Figure 5: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Kineret ($m), 2008–2024 45
Figure 6: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Arcalyst ($m), 2008–2024 47
Figure 7: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Tracleer ($bn), 2006–2024 49
Figure 8: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Thalomid ($m), 2006–2024 52
Figure 9: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Medrol ($m), 2008–2024 55
Figure 10: Orphan and Rare Dermatology Drugs Market, US, Annual Revenue for Rayos ($bn), 2013–2024 57
Figure 11: Orphan and Rare Dermatology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 58
Figure 12: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Stage of Development, Molecule Type and Program Type, 2018 60
Figure 13: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 61
Figure 14: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 62
Figure 15: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Molecular Target and Stage of Development, 2018 64
Figure 16: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 65
Figure 17: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2018 69
Figure 18: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018 69
Figure 19: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018 70
Figure 20: Orphan and Rare Dermatology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018 71
Figure 21: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Epidiolex ($m), 2019–2024 73
Figure 22: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Episalvan (birch bark extract) ($m), 2020–2024 74
Figure 23: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for KB-103 ($m), 2021–2024 75
Figure 24: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Givosiran ($m), 2019–2024 76
Figure 25: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for EB-101 ($m), 2020–2024 78
Figure 26: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for OTL-103 ($m), 2021–2024 79
Figure 27: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Siponimod ($m), 2021–2024 80
Figure 28: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for FCX-007 ($m), 2021–2024 81
Figure 29: Orphan and Rare Dermatology Drugs Market, Global, Premium Product Market Size ($bn), 2017–2024 83
Figure 30: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins ($m), 2017–2024 86
Figure 31: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-a ($m), 2017–2024 87
Figure 32: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Tyrosine Protein Kinases ($m), 2019–2024 88
Figure 33: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Receptors ($m), 2017–2024 89
Figure 34: Orphan and Rare Dermatology Drugs Market, Global, Company Analysis Matrix, 2017–2024 90
Figure 35: Orphan and Rare Dermatology Drugs Market, Global, Cluster by CAGR and Market Share, 2017–2024 91
Figure 36: Orphan and Rare Dermatology Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024 95
Figure 37: Orphan and Rare Dermatology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024 96
Figure 38: Orphan and Rare Dermatology Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024 97
Figure 39: Orphan and Rare Dermatology Drugs Market, Global, Novartis Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 98
Figure 40: Orphan and Rare Dermatology Drugs Market, Global, GW Pharmaceuticals Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 99
Figure 41: Orphan and Rare Dermatology Drugs Market, Global, AbbVie Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 100
Figure 42: Orphan Dermatology Drugs Market, Global, Roche Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2018–2024 101
Figure 43: Orphan and Rare Dermatology Drugs Market, Global, Pfizer Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 102
Figure 44: Orphan and Rare Dermatology Drugs Market, Global, Amryt Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 103
Figure 45: Orphan and Rare Dermatology Drugs Market, Global, GlaxoSmithKline Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2018–2024 104
Figure 46: Orphan and Rare Dermatology Drugs Market, Global, Celgene Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017–2024 105
Figure 47: Orphan and Rare Dermatology Drugs Market, Global, Late-Stage Pipeline Developers by Type, 2018 106
Figure 48: Orphan and Rare Dermatology Drugs Market, Global, Pipeline and Late-Stage Developers by Level of Orphan and Rare Dermatology Specialization, 2018 107
Figure 49: Orphan and Rare Dermatology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Orphan and Rare Dermatology, 2024 108
Figure 50: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006–2018 110
Figure 51: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Indication, 2006–2018 111
Figure 52: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018 112
Figure 53: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018 113
Figure 54: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 114
Figure 55: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018 115
Figure 56: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Key Indication, 2006–2018 116
Figure 57: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018 117
Figure 58: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018 118
Figure 59: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 119
Figure 60: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 1) 129
Figure 61: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 2) 130
Figure 62: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 3) 131
Figure 63: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 4) 132
Figure 64: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 5) 133
Figure 65: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 6) 134
Figure 66: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 7) 135